(Total Views: 556)
Posted On: 11/08/2022 3:06:39 PM
Post# of 148894
Yes Hulk767, that statement is bold: "LL would become the "standard of care" for NASH and TNBC."
He also said in the first CC:
"In breast cancer, rather than focus on only the mTNBC population, which really only represents about 15% of the total growth cancer market and has seen increased competition advancements in check point inhibitors and antibody drug conjugates, we are going expand our focus into Hormone receptor positive HER2 negative population which stands for roughly about 70% of the total market."
He also said in the first CC:
"In breast cancer, rather than focus on only the mTNBC population, which really only represents about 15% of the total growth cancer market and has seen increased competition advancements in check point inhibitors and antibody drug conjugates, we are going expand our focus into Hormone receptor positive HER2 negative population which stands for roughly about 70% of the total market."
(6)
(0)Scroll down for more posts ▼
